Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov 16;11(11):CD009178.
doi: 10.1002/14651858.CD009178.pub3.

Pharmacotherapies for sleep disturbances in dementia

Jenny McCleery  1 , Daniel A Cohen, Ann L Sharpley
Affiliations
Review

Pharmacotherapies for sleep disturbances in dementia

Jenny McCleery et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Sleep disturbances, including reduced nocturnal sleep time, sleep fragmentation, nocturnal wandering, and daytime sleepiness are common clinical problems in dementia, and are associated with significant caregiver distress, increased healthcare costs, and institutionalisation. Drug treatment is often sought to alleviate these problems, but there is significant uncertainty about the efficacy and adverse effects of the various hypnotic drugs in this vulnerable population.

Objectives: To assess the effects, including common adverse effects, of any drug treatment versus placebo for sleep disorders in people with dementia, through identification and analysis of all relevant randomised controlled trials (RCTs).

Search methods: We searched ALOIS (www.medicine.ox.ac.uk/alois), the Cochrane Dementia and Cognitive Improvement Group's Specialized Register, in March 2013 and again in March 2016, using the terms: sleep, insomnia, circadian, hypersomnia, parasomnia, somnolence, rest-activity, sundowning.

Selection criteria: We included RCTs that compared a drug with placebo, and that had the primary aim of improving sleep in people with dementia who had an identified sleep disturbance at baseline. Trials could also include non-pharmacological interventions, as long as both drug and placebo groups had the same exposure to them.

Data collection and analysis: Two review authors independently extracted data on study design, risk of bias, and results from the included study reports. We obtained additional information from study authors where necessary. We used the mean difference as the measure of treatment effect, and where possible, synthesized results using a fixed-effect model.

Main results: We found six RCTs eligible for inclusion for three drugs: melatonin (222 participants, four studies, but only two yielded data on our primary sleep outcomes suitable for meta-analysis), trazodone (30 participants, one study), and ramelteon (74 participants, one study, no peer-reviewed publication, limited information available).The participants in the trazodone study and almost all participants in the melatonin studies had moderate-to-severe dementia due to Alzheimer's disease (AD); those in the ramelteon study had mild-to-moderate AD. Participants had a variety of common sleep problems at baseline. All primary sleep outcomes were measured using actigraphy. In one study of melatonin, drug treatment was combined with morning bright light therapy. Only two studies made a systematic assessment of adverse effects. Overall, the evidence was at low risk of bias, although there were areas of incomplete reporting, some problems with participant attrition, related largely to poor tolerance of actigraphy and technical difficulties, and a high risk of selective reporting in one trial that contributed very few participants. The risk of bias in the ramelteon study was unclear due to incomplete reporting.We found no evidence that melatonin, at doses up to 10 mg, improved any major sleep outcome over 8 to 10 weeks in patients with AD who were identified as having a sleep disturbance. We were able to synthesize data for two of our primary sleep outcomes: total nocturnal sleep time (mean difference (MD) 10.68 minutes, 95% CI -16.22 to 37.59; N = 184; two studies), and the ratio of daytime sleep to night-time sleep (MD -0.13, 95% CI -0.29 to 0.03; N = 184; two studies). From single studies, we found no difference between melatonin and placebo groups for sleep efficiency, time awake after sleep onset, or number of night-time awakenings. From two studies, we found no effect of melatonin on cognition or performance of activities of daily living (ADL). No serious adverse effects of melatonin were reported in the included studies. We considered this evidence to be of low quality.There was low-quality evidence that trazodone 50 mg given at night for two weeks improved total nocturnal sleep time (MD 42.46 minutes, 95% CI 0.9 to 84.0; N = 30; one study), and sleep efficiency (MD 8.53%, 95% CI 1.9 to 15.1; N = 30; one study) in patients with moderate-to-severe AD, but it did not affect the amount of time spent awake after sleep onset (MD -20.41, 95% CI -60.4 to 19.6; N = 30; one study), or the number of nocturnal awakenings (MD -3.71, 95% CI -8.2 to 0.8; N = 30; one study). No effect was seen on daytime sleep, cognition, or ADL. No serious adverse effects of trazodone were reported.Results from a phase 2 trial investigating ramelteon 8 mg administered at night were available in summary form in a sponsor's synopsis. Because the data were from a single, small study and reporting was incomplete, we considered this evidence to be of low quality in general terms. Ramelteon had no effect on total nocturnal sleep time at one week (primary outcome) or eight weeks (end of treatment) in patients with mild-to-moderate AD. The synopsis reported few significant differences from placebo for any sleep, behavioural, or cognitive outcomes; none were likely to be of clinical significance. There were no serious adverse effects from ramelteon.

Authors' conclusions: We discovered a distinct lack of evidence to help guide drug treatment of sleep problems in dementia. In particular, we found no RCTs of many drugs that are widely prescribed for sleep problems in dementia, including the benzodiazepine and non-benzodiazepine hypnotics, although there is considerable uncertainty about the balance of benefits and risks associated with these common treatments. From the studies we identified for this review, we found no evidence that melatonin (up to 10mg) helped sleep problems in patients with moderate to severe dementia due to AD. There was some evidence to support the use of a low dose (50 mg) of trazodone, although a larger trial is needed to allow a more definitive conclusion to be reached on the balance of risks and benefits. There was no evidence of any effect of ramelteon on sleep in patients with mild to moderate dementia due to AD. This is an area with a high need for pragmatic trials, particularly of those drugs that are in common clinical use for sleep problems in dementia. Systematic assessment of adverse effects is essential.

PubMed Disclaimer

Conflict of interest statement

Jenny McCleery: nothing to declare Daniel A Cohen: nothing to declare Ann L Sharpley: nothing to declare

Figures

1
1
Study flow diagram
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Melatonin versus placebo, outcome: 1.1 total night‐time sleep time (minutes)
5
5
Forest plot of comparison: 1 Melatonin versus placebo, outcome: 1.5 ratio of daytime sleep to night‐time sleep
1.1
1.1. Analysis
Comparison 1 Melatonin versus placebo: efficacy, Outcome 1 total nocturnal sleep time (minutes).
1.2
1.2. Analysis
Comparison 1 Melatonin versus placebo: efficacy, Outcome 2 sleep efficiency.
1.3
1.3. Analysis
Comparison 1 Melatonin versus placebo: efficacy, Outcome 3 nocturnal time awake (minutes).
1.4
1.4. Analysis
Comparison 1 Melatonin versus placebo: efficacy, Outcome 4 number of night‐time awakenings.
1.5
1.5. Analysis
Comparison 1 Melatonin versus placebo: efficacy, Outcome 5 ratio of daytime sleep to night‐time sleep.
1.6
1.6. Analysis
Comparison 1 Melatonin versus placebo: efficacy, Outcome 6 carer‐rated sleep quality, change from baseline.
1.7
1.7. Analysis
Comparison 1 Melatonin versus placebo: efficacy, Outcome 7 MMSE, change from baseline.
1.8
1.8. Analysis
Comparison 1 Melatonin versus placebo: efficacy, Outcome 8 ADAS‐cog, change from baseline.
1.9
1.9. Analysis
Comparison 1 Melatonin versus placebo: efficacy, Outcome 9 ADL, change from baseline.
2.1
2.1. Analysis
Comparison 2 Melatonin versus placebo: safety, Outcome 1 number of adverse event reports per person.
2.2
2.2. Analysis
Comparison 2 Melatonin versus placebo: safety, Outcome 2 adverse event severity.
2.3
2.3. Analysis
Comparison 2 Melatonin versus placebo: safety, Outcome 3 reporting at least one adverse event.
3.1
3.1. Analysis
Comparison 3 trazodone AEs, Outcome 1 reporting at least one adverse event.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Camargos 2014 {published data only}
    1. Camargos EF, Louzada LL, Quintas JL, Naves JOS, Louzada FM, Nobrega OT. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double‐blind and placebo‐controlled study. American Journal of Geriatric Psychiatry 2014 [Epub 2014 Jan 4];22(12)(12):1565‐74. [DOI: 10.1016/j.jagp.2013.12.174] - DOI - PubMed
    1. Camargos EF, Quintas JL, Louzada LL, Naves JOS, Furioso ACT, Nobrega OT. Trazodone and cognitive performance in Alzheimer disease. Journal of clinical psychopharmacology 2015;35(1):88‐9. - PubMed
Dowling 2008 {published data only}
    1. Dowling GA, Burr RL, Someren EJW, Hubbard EM, Luxenberg JS, Mastick J, et al. Melatonin and bright light treatment for rest‐activity disruption in institutionalized patients with Alzheimer's disease. American Journal of Geriatric Psychiatry 2008;56(2):239‐46. - PMC - PubMed
NCT00325728 {published data only (unpublished sought but not used)}
    1. NCT00325728. A double‐blind, randomized, placebo‐controlled study of the efficacy, safety and tolerability of 8 week treatment of Rozerem 8 mg (QHS) in sleep disturbed, mild to moderately severe Alzheimer's disease subjects. clinicaltrials.gov/ct2/show/NCT00325728?.
    1. NCT00325728. Clinical Trial Synopsis 01‐05‐TL‐375‐061, NCT#00325728: A double‐blind, randomized, placebo‐controlled study of the efficacy, safety and tolerability of 8 week treatment of Rozerem 8 mg (QHS) in sleep disturbed, mild to moderately severe Alzheimer’s disease subjects. www.takeda.com/research/ct/pdf/report/15_Ramelteon_01‐05‐TL‐375‐061_Clin....
Serfaty 2002 {published data only}
    1. Serfaty M, Kennell‐Webb S, Warner J, Blizard R, Raven P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. International Journal of Geriatric Psychiatry 2002;17(12):1120‐7. - PubMed
Singer 2003 {published data only}
    1. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, et al. A multicenter, placebo‐controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003;26(7):893‐901. - PMC - PubMed
Wade 2014 {published data only}
    1. Wade AG, Farmer M, Harari H, Fund N, Laudon M, Nir T, et al. Add‐on prolonged‐release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6‐month, randomized, placebo‐controlled, multicenter trial. Clinical Interventions in Aging 2014;9:947‐61. [10.2147/CIA.S65625. eCollection 2014] - PMC - PubMed

References to studies excluded from this review

Asano 2013 {published data only}
    1. Asano M, Ishitobi M, Tanaka Y, Wada Y. Effects of ramelteon on refractory behavioral and psychological symptoms of Alzheimer's disease. Journal of Clinical Psychopharmacology 2013;33(4):579‐81. [DOI: 10.1097/JCP.0b013e3182946702] - DOI - PubMed
Asayama 2003 {published data only}
    1. Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S. Double blind study of melatonin effects on the sleep‐wake rhythm, cognitive and non‐cognitive functions in Alzheimer type dementia. Journal of Nippon Medical School 2003;70:334‐41. - PubMed
Bergener 1968 {published data only}
    1. Bergener M, Undeutsch D. Methods and problems of clinical psychopharmacology. Results of a double blind study with Medazepam and placebo in geriatric psychiatry. Arzneimittel‐Forschung 1968;18:1563‐6. - PubMed
Bergonzi 1973 {published data only}
    1. Bergonzi P, Capocchi G, Chiurulla C, Mennuni G, Tempsta E. Tryptophan and sleep in subjects with neuropsychiatric syndromes. Rivista di Neurologia 1973;43:403‐9. - PubMed
Cardinali 2014 {published data only}
    1. Cardinali DP, Vigo DE, Natividad O, Vidal MF, Brusco LI. Melatonin therapy in patients with Alzheimer's disease. Antioxidants 2014;2:245‐77. - PMC - PubMed
Cohen‐Mansfield 2000 {published data only}
    1. Cohen‐Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia – a preliminary study. Archives of Gerontology and Geriatrics 2000;31:65‐76. - PubMed
Cruz‐Aguilar 2013 {published data only}
    1. Cruz‐Aguilar MA, Ramirez‐Salado I, Cruz‐Ulloa C, Benitez‐King G. Melatonin effects on macro sleep architecture in Alzheimer's disease patients. Salud Mental 2013;36:243‐9.
Eeles 2003 {published data only}
    1. Eeles E. The effect of melatonin on sleep pattern and levels of agitation in patients with dementia. National Research Register 2003.
Gehrmann 2009 {published data only}
    1. Gehrmann PR, Donald JC, Martin JL, Shochat T, Corey‐Bloom J, Ancoli‐Israel S. Melatonin fails to improve sleep or agitation in a double‐blind randomized placebo‐controlled trial of instituitionalized patients with Alzheinmer's disease. American Journal of Geriatric Psychiatry 2009;17(2):166‐9. - PMC - PubMed
Gillman 1997 {published data only}
    1. GIllman PK. Tacrine for treatment of sleep disturbance in dementia. Journal of the American Geriatrics Society 1997;45:1286. - PubMed
GInsburg 1976 {published data only}
    1. Ginsburg R, Weintraub M. Caffeine in the 'Sundown syndrome'. Report of negative results. Journal of Gerontology 1976;31:419‐20. - PubMed
Haworth 2001 {published data only (unpublished sought but not used)}
    1. Haworth J. A pilot, double‐blind, placebo controlled, parallel group study of the effect of melatonin treatment in patients with Alzheimer's disease and sleep. National Research Register Archive 2001.
Howcroft 2005 {published data only}
    1. Howcroft DJ, Jones RW. Does modafinil have the potential to improve disrupted sleep patterns in patients with dementia?. International Journal of Geriatric Psychiatry 2005;20:492‐5. - PubMed
Kittur 1999 {published data only}
    1. Kittur S, Hause P. Improvement of sleep and behavior by methylphenidate in Alzheimer's disease. American Journal of Psychiatry 1999;156:1116‐7. - PubMed
Linnoila 1980a {published data only}
    1. Linnoila M, Viukari M, Numminen A, Auvinen J. Efficacy and side effects of chloral hydrate and tryptophan as sleeping aids in psychogeriatric patients. International Pharmacopsychiatry 1980;15:124‐8. - PubMed
Linnoila 1980b {published data only}
    1. Linnoila M, Viukari M, Lamminsivu U, Auvinen J. Efficacy and side effects of lorazepam, oxazepam, and temazepam as sleeping aids in psychogeriatric in‐patients. International Pharmacopsychiatry 1980;15:129‐35. - PubMed
Magnus 1978 {published data only}
    1. Magnus RV. A controlled trial of chlormethiazole in the management of symptoms of the organic dementias in the elderly. Clinical Therapeutics 1978;1(6):387‐96.
Mahlberg 2004 {published data only}
    1. Mahlberg R, ‭ ‬Kunz D, ‭ ‬Sutej I, ‭ ‬Kuhl KP, ‭ Hellweg R. Melatonin treatment of day‐night rhythm disturbances and sundowning in Alzheimer disease:‭ ‬an open‐label pilot study using actigraphy. Journal of Clinical Psychopharmacology 2004;24:456‐9. - PubMed
Markowitz 2003 {published data only}
    1. Markowitz JS, Gutterman EM, Lilienfeld S, Papadopoulos G. Sleep‐related outcomes in persons with mild to moderate Alzheimer disease in a placebo‐controlled trial of galantamine. Sleep 2003;26:602‐6. - PubMed
Meguro 2004 {published data only}
    1. Meguro K, Meguro M, Tanaka Y, Akanuma K, Yamaguchi K, Itoh M. Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology 2004;17:61‐7. - PubMed
Mishima 1992 {published data only}
    1. Mishima K, Okawa M, Hishikawa Y. Effect of methylcobalamin (VB12) injection on sleep‐wake rhythm in demented patients. Japanese Journal of Psychiatry & Neurology 1992;46:227‐8. - PubMed
Moraes 2003 {published data only}
    1. Moraes WA, Poyares DL, Ramos LR, Bertolucci PH, Tufik S. Six‐month donepezil treatment alters REM sleep parameters in Alzheimer's disease patients: a double‐blind placebo controlled study. Sleep 2003;26:A351. - PubMed
Moraes 2006 {published data only}
    1. Moraes WA, Poyares DR, Guilleminault C, Ramos LR, Ferreira Bertolucci PH, Tufik S. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double‐blind placebo‐controlled study. Sleep 2006;29:199‐205. - PubMed
NCT00035204 {published data only}
    1. NCT00035204. A study of the effects on sleep, attention, and gastrointestinal tolerance of galantamine and donepezil in patients with Alzheimer's disease. clinicaltrials.gov/show/NCT00035204 (first received 2 May 2002).
NCT00480870 {published data only}
    1. NCT00480870. The effect of anticholinesterase drugs on sleep in Alzheimer's disease patients. clinicaltrials.gov/show/NCT00480870 (first received 30 May 2007).
NCT00626210 {published data only}
    1. NCT00626210. Modafinil treatment for sleep/wake disturbances in older adults. clinicaltrials.gov/show/NCT00626210 (first received 20 February 2008).
NCT00706186 {published data only}
    1. NCT00706186. Safety and feasibility of sodium oxybate in mild Alzheimer's disease patients. clinicaltrials.gov/show/NCT00706186 (first received 24 June 2008).
NCT00940589 {published data only}
    1. NCT00940589. Efficacy of Circadin® 2 mg in patients with mild to moderate Alzheimer disease treated with AChE inhibitor. clinicaltrials.gov/show/NCT00940589 (first received 15 July 2009).
NCT01548287 {published data only}
    1. NCT01548287. A study of the safety and tolerability of AZD5213 effect on sleep for patients with Alzheimer's/cognitive impairment. clinicaltrials.gov/show/NCT01548287 (first received 5 March 2012).
Petit 1993 {published data only}
    1. Petit G, Montplaisir J, Lorrain D, Gauthier S. THA does not affect sleep or EEG spectral power in Alzheimer's disease. Biological Psychiatry 1993;33:753‐4. - PubMed
Riemersma‐van der Lek2008 {published data only}
    1. Riemersma‐van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJG, Someren EJW. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 2008;299:2642‐55. - PubMed
Riley McCarten 1995 {published data only}
    1. Riley McCarten J, Kovera C, Maddox MK, Cleary JP. Triazolam in Alzheimer's disease: pilot study on sleep and memory effects. Pharmacology, Biochemistry and Behavior 1995;52:447‐52. - PubMed
Ruths 2004 {published data only}
    1. Ruths S, Straand J, Nygaard HA, Bjorvatn B, Pallesen S. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo‐controlled, double‐blinded study. Journal of the American Geriatrics Society 2004;52:1737‐43. - PubMed
Schubert 1984 {published data only}
    1. Schubert DS. Hydroxyzine for acute treatment of agitation and insomnia in organic mental disorder. Psychiatric Journal of the University of Ottawa 1984;9:59‐60. - PubMed
Scoralick 2016 {published data only}
    1. Scoralick FM, Louzada LL, Quintas JL, Naves JOS, Camargos EF, Nobrega OT. Mirtazapine does not improve sleep disorders in Alzheimer's disease: results from a double‐blind, placebo‐controlled pilot study. Psychogeriatrics 2016 Jan 27 [Epub ahead of print]:1‐8. [DOI: 10.1111/psyg.12191] - DOI - PubMed
Scripnikov 2007 {published data only}
    1. Scripnikov A, Khomenko A, Napryeyenko O. Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wiener Medizinische Wochenschrift 2004;157:295‐300. - PubMed
Shaw 1992 {published data only}
    1. Shaw SH, Curson H, Coquelin JP. A double‐blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in‐patients. Journal of International Medical Research 1992;20:150‐61. - PubMed
Shinno 2008 {published data only}
    1. Shinno H, ‭ ‬Inami Y, ‭ ‬Inagaki T, ‭ ‬Nakamura Y, ‭ Horiguchi J. Effect of Yi‐Gan San on psychiatric symptoms and sleep structure at patients with behavioral and psychological symptoms of dementia. Progress in Neuro‐Psychopharmacology‭ & ‬Biological Psychiatry 2008;32:881‐5. - PubMed
Simon Padilla 2009 {published data only}
    1. Simon Padilla OJ, Linares Del Rio C, Godden P, Granizo E, Pinilla M, Rodriguez C. Use of combined treatment with melatonin and clomethiazole in circadian rhythm sleep disorder in the elderly with dementia. Revista Espanola de Geriatria y Gerontologia 2009;44:233‐4. - PubMed
Singer 2007 {published data only}
    1. Singer CM, Nanda F. Modafinil vs. placebo: effects on daytime sleep in Alzheimer's disease. Biological Psychiatry 2007;61:144S.
Stahl 2004 {published data only}
    1. Stahl SM, Markowitz JS, Papadopoulos G, Sadik K. Examination of nighttime sleep‐related problems during double‐blind, placebo‐controlled trials of galantamine in patients with Alzheimer's disease. Current Medical Research and Opinion 2004;20:517‐25. - PubMed
Stemmelin 2013 {published data only}
    1. Stemmelin J, Kirkesseli S, Martincova R, Bejuit R, Corp‐Dit‐Genti V, Morrison G, et al. A phase 2 study to investigate the effects of Sar110894 on cognition, daily function, apathy and sleep in mild to moderate Alzheimer's disease patients. Journal of Nutrition, Health and Aging: 6th Conference Clinical Trials on Alzheimer's Disease. 2013:804‐5.
Tozawa 1998 {published data only (unpublished sought but not used)}
    1. Tozawa T, ‭ ‬Mishima K, ‭ ‬Satoh K, ‭ ‬Matsumoto Y, ‭ ‬Echizenya M, ‭ ‬Sasaki M, ‭ ‬et al. Melatonin replacement therapy for rest‐activity rhythm disorders in patients with senile dementia of Alzheimer's type. ‬21st Collegium Internationale Neuropsychopharmacologium‭ (‬CINP‭) ‬Congress, 1998 Jul‭ ‬12‐16‭; Glasgow,‭ ‬Scotland. 1998.
UMIN000006388 {published data only}
    1. JPRN‐UMIN000006388. Investigation on the effects of memantine on psychiatric symptoms and sleep disturbances in patients with Alzheimer's disease. upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000007581 (disclosed on 21 September 2011).
UMIN000016374 {published data only}
    1. UMIN000016374. The controlled study of medical treatment for the sleep disturbance in dementia. upload.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000019016 (date of disclosure 29 January 2015).
Valtonen 2005 {published data only}
    1. Valtonen M, Niskanen L, Kangas A‐P, Koskinen T. Effects of melatonin‐rich night‐time milk on sleep and activity in elderly institutionalized subjects. Nordic Journal of Psychiatry 2005;59:217‐21. - PubMed
Walther 2011 {published data only}
    1. Walther S, Shüpbach B, Seifritz E, Strik W. Randomized, controlled, crossover trial of dronabinol, 2.5mg, for agitation in 2 patients with dementia. Journal of Clinical Psychopharmacology 31(2): 254‐6 2011. - PubMed
Yehuda 1996 {published data only}
    1. Yehuda S, Rabinovtz S, Carasso RL, Mostofsky DI. Essential fatty acids preparation (sr‐3) improves Alzheimer's patients quality of life. International Journal of Neuroscience 1996;87:141‐9. - PubMed

References to studies awaiting assessment

NCT00814502 {published data only}
    1. Zolpidem CR and hospitalized patients with dementia. ClinicalTrials.gov.

Additional references

Ancoli‐Israel 1997
    1. Ancoli‐Israel S, Clopton P, Klauber MR, Fell R, Mason W. Use of wrist actigraphy for monitoring sleep/wake in demented nursing home patients. Sleep 1997;20:24‐7. - PMC - PubMed
Bliwise 2011
    1. Bliwise DL, Mercaldo ND, Avidan AY, Boeve BF, Greer SA, Kukull WA. Sleep disturbance in dementia with Lewy bodies and Alzheimer's disease: a multicenter analysis. Dementia & Geriatric Cognitive Disorders 2011;31(3):239‐46. - PMC - PubMed
Buxton 2000
    1. Buxton OM, Copinschi G, Onderbergen A, Karrison TG, Cauter E. A benzodiazepine hypnotic facilitates adaptation of circadian rhythms and sleep‐wake homeostasis to an eight hour delay shift simulating westward jet lag. Sleep 2000;23:915‐27. - PubMed
Camargos 2013
    1. Camargos EF, Louzarda FM, Nobrega OT. Wrist actigraphy for measuring sleep in intervention studies with Alzheimer's disease patients: application, usefulness and challenges. Sleep Medicine Reviews 2013;17:475‐88. - PubMed
Cardinali 2010
    1. Cardinali DP, Furio AM, Brusco LI. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Current Neuropharmacology 2010;8:218‐27. - PMC - PubMed
Closser 1991
    1. Closser MH. Benzodiazepines and the elderly: a review of potential problems. Journal of Substance Abuse Treatment 1991;8:35‐41. - PubMed
Coupland 2011
    1. Coupland CA, Dhiman P, Barton G, Morriss R, Arthur A, Sach T, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technology Assessment 2011;15(28):1‐202. - PubMed
Cumming 2003
    1. Cumming RG, Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003;17:825‐37. - PubMed
Dauvilliers 2007
    1. Dauvilliers Y. Insomnia in patients with neurodegenerative conditions. Sleep Medicine 2007;4 Suppl:27‐34. - PubMed
David 2010
    1. David R, Zeitzer J, Friedman L, Noda A, O'Hara R, Robert P, et al. Non‐pharmacologic management of sleep disturbance in Alzheimer's disease. The Journal of Nutrition, Health & Aging 2010;14:203‐6. - PubMed
Donaldson 1998
    1. Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer’s disease. International Journal of Geriatric Psychiatry 1998;13:248‐56. - PubMed
Fuh 2005
    1. Fuh J‐L, Wang S‐J, Cummings JL. Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia. Journal of Neurology, Neurosurgery and Psychiatry 2005;76(10):1337‐41. - PMC - PubMed
Gao 2009
    1. Gao QW, LIU Y, Luo GQ, Xiang W, Peng KR. Effect of melatonin on mild Alzheimer's disease in elderly male patients. Practical Geriatrics 2009;23(1):56‐8.
Gaugler 2000
    1. Gaugler JE, Edwards AB, Femia EE, Zarit SH, Parris Stevens M‐A, Townsend A, et al. Predictors of institutionalization of cognitively impaired elders: family help and the timing of placement. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences 2000;55:247‐55. - PubMed
Guyatt 2011
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383‐94. - PubMed
Hart 2003
    1. Hart DJ, Craig D, Compton SA, Critchlow S, Kerrigan B, McIlroy SP, et al. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease. International Journal of Geriatric Psychiatry 2003;18(11):1037‐42. - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Howard 2011
    1. Howard R, Phillips P, Johnson T, O'Brien J, Sheehan B, Lindesay J, et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry 2011;26(8):812‐7. - PubMed
Mishima 2000
    1. Mishima K, Okawa M, Hozumi S, Hishikawa Y. Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest‐activity and dysfunctional autonomic and neuroendocrine systems in institutionalzed demented elderly persons. Chronobiology International 2000;17(3):419‐32. - PubMed
Montplaisir 1995
    1. Montplaisir J, Petit D, Lorrain D, Gauthier S, Nielsen T. Sleep in Alzheimer's disease: further considerations on the role of brainstem and forebrain cholinergic populations in sleep‐wake mechanisms. Sleep 1995;18:145‐8. - PubMed
Montplaisir 1998
    1. Montplaisir J, Petit D, Gauthier S, Gaudreau H, Decary A. Sleep disturbances and EEG slowing in Alzheimer's disease. Sleep Research Online 1998;1(4):147‐51. - PubMed
Oderda 2012
    1. Oderda LH, Young JR, Asche CV, Pepper GA. Psychotropic‐related hip fractures: meta‐analysis of first‐generation and second‐generation antidepressant and antipsychotic drugs. Annals of Pharmacotherapy 2012;46:917‐28. - PubMed
Rongve 2010
    1. Rongve A, Boeve BF, Aarsland D. Frequency and correlates of caregiver‐reported sleep disturbances in a sample of persons with early dementia. Journal of the American Geriatrics Society 2010;58(3):480‐6. - PubMed
Swaab 1985
    1. Swaab DF, Fliers E, Partiman TS. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Research 1985;342:37‐44. - PubMed
Van Someren 2000
    1. Someren EJW. Circadian rhythms and sleep in human aging. Chronobiology International 2000;17:233‐43. - PubMed
Vitiello 1991
    1. Vitiello MV, Poceta JS, Prinz PN. Sleep in Alzheimer’s disease and other dementing disorders. Canadian Journal of Psychology 1991;45:221‐39. - PubMed
Wilfling 2015
    1. Wilfling D, Junghans A, Marshall L, Eisemann N, Meyer G, Moehler R, et al. Non‐pharmacological interventions for sleep disturbances in people with dementia. Cochrane Database of Systematic Reviews 2015, Issue 9. [DOI: 10.1002/14651858.CD011881] - DOI - PMC - PubMed
Xu 2015
    1. Xu J, Wang LL, Dammer EB, Li CB, Xu G, Chen SD, et al. Melatonin for sleep disorders and cognition in dementia: a meta‐analysis of randomized controlled trials. American Journal of Alzheiner's Disease and Other Dementias 2015;30(5):439‐47. - PMC - PubMed

LinkOut - more resources